Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEAP-015 first-line pembrolizumab + lenvatinib + chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma
MOH_2020-11-25_009357Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and lenvatinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Merck & Co. Primary endpoints: Safety and tolerability, Overall survival and 1 more. Started Nov 2020; status: completed.
02
Drugs
pembrolizumablenvatinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on MOH_2020-11-25_009357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-11-25_009357.